# US 2022/0276265 A9 · Methods for Identifying Risk of Chemotherapy-Induced Cardiotoxicity and Targeted Medical Intervention

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0276265 A9
- Document ID: US20220276265A9
- Status: Published application
- Kind: A9
- Application number: 16/259,499
- Filed: 2019-01-28
- Published: 2022-09-01
- Earliest claimed: 2018-01-30
- Assignees: Detroit R&D, Inc.
- Inventors: Hyesook Kim
- Web page: https://patentgrep.com/patent/US20220276265A9

## CPC

- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 33/573: for enzymes or isoenzymes
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- G01N 2405/00: Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N 2560/00: Chemical aspects of mass spectrometric analysis of biological material
- G01N 2800/32: Cardiovascular disorders
- G01N 2800/42: Poisoning, e.g. from bites or stings
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention discloses diagnosis of risk of chemotherapy-induced cardiotoxicity by measurement of increased expression of soluble epoxide hydrolase in vitro and in vivo in cells, tissues or animals including measurement of increased levels of soluble epoxide hydrolase metabolites, e.g., 14,15-DHET and 11,12-DHET, in biological fluids. This invention also includes diagnosis of risk of chemotherapy-induced cardiotoxicity by measuring increased levels of oxidative stress in cells, tissues or animals including measurement of increased levels of oxidative stress biomarkers, e.g., 8-isoprostane, in biological fluids. Fatty acid and protein biomarkers to diagnose the risk of chemotherapy-induced cardiotoxicity are detected using various detection methods including mass spectrometry and immunoassay such as ELISA, Western blot analysis or label-free microwell and nanowell technologies. This invention discloses targeted medical intervention for a subject who is at risk or with chemotherapy-induced cardiotoxicity by treating with soluble epoxide hydrolase inhibitor(s) with or without antioxidants to prevent or ameliorate the chemotherapy-induced cardiotoxicity.

## Claims

### Claim 1

A method to identify risk of chemotherapy-induced cardiotoxicity using biomarkers that predict cardiotoxicity by the steps of:
determining early cardiotoxicity biomarker levels in biological samples including biological fluids and
Identifying the increased level of the biomarker compared to control sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the chemotherapy-induced cardiotoxicity is induced by an anthracycline, a DNA/RNA intercalator, such as doxorubicin, daunorubicin, epirubicin and idarubicin.

### Claim 3 (depends on 2)

The method of claim 2, wherein early cardiotoxicity biomarker is a metabolite of soluble epoxide hydrolase.

### Claim 4 (depends on 3)

The method of claim 3, wherein the metabolite is 14,15-DHET or 11,12-DHET.

### Claim 5 (depends on 4)

The method of claim 4, wherein the sEH metabolites are determined by mass spectrometry or immunoassay including ELISA, dot blot analysis or lateral flow (dipstick) immunoassay or label-free microwell and nanowell technologies.

### Claim 6 (depends on 2)

The method of claim 2, wherein early cardiotoxicity biomarker is 8-isoprostane.

### Claim 7 (depends on 2)

The method of claim 2, wherein multiple early cardiotoxicity biomarkers consisted of 14,15-DHET and 8-isoprostane.

### Claim 8 (depends on 7)

The method of claim 7, wherein with multiple early cardiotoxicity biomarkers consisted of increased levels of 14,15-DHET, 8-isoprostane, troponin I (TnI), myeloperoxidase (MPO) and/or GDF-15 (NAG-1).

### Claim 9 (depends on 2)

The method of claim 2, wherein early cardiotoxicity biomarker is the increased brain natriuretic peptide (BNP) level.

### Claim 10

A method to identify sEH-dependent cardiotoxicity after chemotherapy using a metabolite of sEH by the steps of:
determining the 14,15-DHET level in biological fluids and
Identifying the increased 14,15-DHET level compared to control sample.

### Claim 11 (depends on 10)

The method of claim 10, wherein the cardiotoxicity is induced by an anthracycline, a DNA/RNA intercalator, such as doxorubicin, daunorubicin, epirubicin and idarubicin.

### Claim 12 (depends on 11)

The method of claim 11, wherein the chemotherapy-associated cardiotoxicity is diagnosed with cardiovascular disease biomarkers or a reduction of left ventricular ejection fraction (LVEF).

### Claim 13 (depends on 12)

The method of claim 12, wherein the sEH metabolites are determined by mass spectrometry or immunoassays including ELISA, dot blot analysis and lateral flow (dipstick) immunoassay or label-free microwell and nanowell technologies.

### Claim 14 (depends on 13)

The method of claim 13, wherein with multi-cardiotoxicity biomarkers consisted of 14,15-DHET, 8-isoprostane, troponin I (TnI), myeloperoxidase (MPO) and/or GDF-15 (NAG-1).

### Claim 15 (depends on 11)

The method of claim 11, wherein cardiotoxicity biomarker is the decreased brain natriuretic peptide (BNP) level.

### Claim 16

Treatment of natural or synthetic soluble epoxide hydrolase inhibitor or a mixture of soluble epoxide hydrolase inhibitors with or without oxidative stress inhibitors to prevent or ameliorate the chemotherapy-induced cardiotoxicity.

### Claim 17 (depends on 16)

The method of claim 16, wherein the inhibitor is honokiol or a honokiol-containing dietary supplement.

### Claim 18

A method to measure fatty acids and proteins in biological samples including biological fluids using label-free microwell or nanowell technology by the steps of:
Measuring cyclic voltammetry or impedance levels of various concentrations of fatty acid or protein using electrodes coated with the antibody or IgG ranging from 1 to 10 μg/ml;
Drawing a standard curve of concentrations of fatty acid or protein vs. cyclic voltammetry or impedance levels (−Z″, Kohm);
Selecting antibody or IgG levels to coat electrode surface; and
Measuring levels of fatty acid or protein in a target biological fluid sample and control sample.

### Claim 19 (depends on 18)

The method of claim 18, wherein the fatty acids are 14,15-DHET, 20-HETE and 8-isoprostane and protein is troponin I (TnI).

### Claim 20 (depends on 19)

The method of claim 19, wherein the limit of detection (LOD) is ≤100 fg/ml.
